IMVT Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 12.65%. Immunovant, Inc.'s return on equity of -88.1% beat Electromed, Inc.'s return on equity of 18.89%.

Immunovant, Inc. has a consensus price target of $38.80, signalling upside risk potential of 69.88%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Immunovant, Inc. has higher upside potential than Electromed, Inc., analysts believe Immunovant, Inc. is more attractive than Electromed, Inc..

Immunovant, Inc. has a beta of 0.557, which suggesting that the stock is 44.254% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Immunovant, Inc.'s net income of -$126.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 6.76%. Immunovant, Inc.'s return on equity of -88.1% beat Revvity, Inc.'s return on equity of 3.05%.

Immunovant, Inc. has a consensus price target of $38.80, signalling upside risk potential of 69.88%. On the other hand Revvity, Inc. has an analysts' consensus of $113.67 which suggests that it could grow by 12.78%. Given that Immunovant, Inc. has higher upside potential than Revvity, Inc., analysts believe Immunovant, Inc. is more attractive than Revvity, Inc..

Immunovant, Inc. has a beta of 0.557, which suggesting that the stock is 44.254% less volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.059, suggesting its more volatile than the S&P 500 by 5.937%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity, Inc. offers a yield of 0.28% to investors and pays a quarterly dividend of $0.07 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Revvity, Inc. pays out 11.63% of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Immunovant, Inc. quarterly revenues are --, which are smaller than Revvity, Inc. quarterly revenues of $698.9M. Immunovant, Inc.'s net income of -$126.5M is lower than Revvity, Inc.'s net income of $47.2M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Revvity, Inc.'s PE ratio is 50.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 4.25x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Immunovant, Inc.'s net margin of -862.39%. Immunovant, Inc.'s return on equity of -88.1% beat VolitionRX Ltd.'s return on equity of --.

Immunovant, Inc. has a consensus price target of $38.80, signalling upside risk potential of 69.88%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Immunovant, Inc., analysts believe VolitionRX Ltd. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.557, which suggesting that the stock is 44.254% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Immunovant, Inc.'s net income of -$126.5M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 3.93%. Immunovant, Inc.'s return on equity of -88.1% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Immunovant, Inc. has a consensus price target of $38.80, signalling upside risk potential of 69.88%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Immunovant, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.557, which suggesting that the stock is 44.254% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Immunovant, Inc.'s net income of -$126.5M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.